BMY
Bristol-Myers Squibb Company
Is BMY Halal?
Large-cap global pharmaceutical company specializing in oncology, hematology, immunology, and cardiovascular medicines — permissible pharmaceutical business.
What You Should Know
Bristol-Myers Squibb develops prescription medicines across oncology, hematology, immunology, cardiovascular and neuroscience categories. Pharmaceutical activity is generally permissible, while product, licensing and clinical allocation remains qualitative. Its March 31, 2026 Form 10-Q reports total assets of $86,476 million, conservative debt and leases of $48,417 million, cash of $9,574 million, debt securities of $1,278 million, receivables of $9,368 million and quarterly revenue of $11,489 million. Debt/assets is 55.99%, liquidity/assets is 12.55%, receivables plus cash/assets is 21.90% and disclosed investment interest/revenue is 0.91%; the examined FTSE, MSCI and Malaysia asset-based financial screens fail.
⚠️ Concerns
- •The current filing-based debt/assets screen is 55.99%, above the examined 33.33% limit
- •Some pharmaceutical products may contain trace animal-derived materials; scholars may apply necessity and treatment-specific reasoning
- •Disclosed investment interest income is $104 million for the quarter; consult a qualified scholar on purification
- •Patent-cliff and acquisition integration are business-quality considerations
- •The filing does not provide a universal prohibited-revenue numerator across all products and licenses
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
48,417 / 86,476
10,852 / 86,476
18,942 / 86,476
104 / 11,489
- Financial
- Fails
- Overall
- Fails
Debt/assets is 55.99%, above the examined 33.333% limit; liquidity/assets is 12.55%, receivables-plus-cash/assets is 21.90% and disclosed interest income is 0.91%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 55.99%, above the examined MSCI 33.33% limit; liquidity/assets is 12.55% and receivables-plus-cash/assets is 21.90%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 55.99%, above the examined Malaysia debt limit; pharmaceutical activity and prohibited-revenue allocation remain qualitative.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed and reproducible historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Bristol Myers Squibb develops and sells prescription medicines in oncology, hematology, immunology, cardiovascular and other therapeutic areas. Pharmaceutical activity is generally permissible, while product and licensing allocation requires qualitative review.
Limitation: The filing does not provide a universal prohibited-revenue numerator across all products, licenses and jurisdictions.
Purification
Bristol Myers Squibb discloses $104 million of investment interest income, but no scholar-approved purification percentage is asserted for the operating business.
Inputs, assumptions and primary sources
- Amounts are USD millions from Bristol Myers Squibb's March 31, 2026 Form 10-Q.
- Conservative debt combines $44,140 million of long-term debt, $2,308 million of short-term borrowings and $1,969 million of operating-lease liabilities.
- Receivables combine $7,946 million of net accounts receivable and $1,422 million of other receivables; debt securities are $912 million current and $366 million noncurrent.
- Quarterly revenue is $11,489 million and disclosed investment interest income is $104 million, or 0.91% of revenue.
- Prescription medicines are generally permissible at the activity level, while product, licensing, clinical and acquisition allocation remains qualitative.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →